# Idorsia (stock symbol: IDIA.SW) Logo in transparent PNG and SVG formats

## Idorsia Logo large

### Idorsia Logo large Download PNG (27.81 KB)

![Idorsia Logo large Download PNG (27.81 KB)](/img/orig/IDIA.SW_BIG-11cdb0c6.png)

### Idorsia Logo large Download SVG (2 KB)

![Idorsia Logo large Download SVG (2 KB)](/img/orig/IDIA.SW_BIG-da136128.svg)

## Idorsia Logo icon format

### Idorsia Logo icon format Download PNG (16.04 KB)

![Idorsia Logo icon format Download PNG (16.04 KB)](/img/orig/IDIA.SW-53c2ae84.png)

### Idorsia Logo icon format Download SVG (530 Bytes)

![Idorsia Logo icon format Download SVG (530 Bytes)](/img/orig/IDIA.SW-e31b545f.svg)

## Idorsia Logo large for dark backgrounds

### Idorsia Logo large for dark backgrounds Download PNG (28.78 KB)

![Idorsia Logo large for dark backgrounds Download PNG (28.78 KB)](/img/orig/IDIA.SW_BIG.D-63a1ba1c.png)

### Idorsia Logo large for dark backgrounds Download SVG (2 KB)

![Idorsia Logo large for dark backgrounds Download SVG (2 KB)](/img/orig/IDIA.SW_BIG.D-5fe78f87.svg)

## Idorsia Logo icon format for dark backgrounds

### Idorsia Logo icon format for dark backgrounds Download PNG (16.44 KB)

![Idorsia Logo icon format for dark backgrounds Download PNG (16.44 KB)](/img/orig/IDIA.SW.D-2b4404e0.png)

### Idorsia Logo icon format for dark backgrounds Download SVG (530 Bytes)

![Idorsia Logo icon format for dark backgrounds Download SVG (530 Bytes)](/img/orig/IDIA.SW.D-b2e2c65b.svg)

## About Idorsia

Idorsia Ltd, a biopharmaceutical company, discovers, develops, and commercializes drugs for unmet medical needs in Switzerland. The company has a clinical development pipeline that cover various therapeutic areas, including CNS, cardiovascular, and immunological disorders, as well as orphan diseases. Idorsia Ltd has a collaboration agreement with Janssen Biotech Inc. to jointly develop and commercialize aprocitentan and its derivative compounds or products; license agreement with Mochida Pharmaceutical for the supply, co-development, and comarketing of daridorexant; and Hoffman-La Roche Inc. to develop and market compounds in the field of cancer immunotherapy. It also has a collaboration with Antares Pharma, Inc. for the development of a self- administered drug device product for Selatogrel; and Neurocrine Biosciences, Inc. to develop and commercialize ACT-709478, which is in Phase II clinical trial for the treatment of epilepsy. The company was incorporated in 2017 and is headquartered in Allschwil, Switzerland.

1. Website domain: idorsia.com
2. Marketcap: $1.73 Billion USD


## Categories
- [x] ðŸ‡¨ðŸ‡­ Switzerland
- [x] ðŸ’Š Pharmaceuticals
- [x] ðŸ§¬ Biotech
